WO1989008144A1 - Bi-affinity chromatography of compounds which have an affinity for two or more ligands - Google Patents
Bi-affinity chromatography of compounds which have an affinity for two or more ligands Download PDFInfo
- Publication number
- WO1989008144A1 WO1989008144A1 PCT/US1988/001660 US8801660W WO8908144A1 WO 1989008144 A1 WO1989008144 A1 WO 1989008144A1 US 8801660 W US8801660 W US 8801660W WO 8908144 A1 WO8908144 A1 WO 8908144A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- column
- eluate
- heparin
- copper
- contacting
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 81
- 239000003446 ligand Substances 0.000 title claims description 43
- 238000001042 affinity chromatography Methods 0.000 title abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 59
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims abstract description 15
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims abstract description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 107
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 95
- 229910052802 copper Inorganic materials 0.000 claims description 54
- 239000010949 copper Substances 0.000 claims description 54
- 239000011780 sodium chloride Substances 0.000 claims description 54
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 51
- 229960002897 heparin Drugs 0.000 claims description 51
- 229920000669 heparin Polymers 0.000 claims description 51
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 50
- 229920002684 Sepharose Polymers 0.000 claims description 26
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 26
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 26
- 229960005356 urokinase Drugs 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 17
- 239000003102 growth factor Substances 0.000 claims description 13
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 12
- 229910052725 zinc Inorganic materials 0.000 claims description 12
- 239000011701 zinc Substances 0.000 claims description 12
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 11
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims description 9
- 239000012501 chromatography medium Substances 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 150000002460 imidazoles Chemical class 0.000 claims description 7
- 239000012266 salt solution Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 239000012190 activator Substances 0.000 abstract 1
- 101150021185 FGF gene Proteins 0.000 description 47
- 239000000523 sample Substances 0.000 description 22
- 238000000746 purification Methods 0.000 description 16
- 241000894007 species Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000000463 material Substances 0.000 description 11
- 108010073863 saruplase Proteins 0.000 description 11
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 8
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- DBYBWCHSXOSECO-UHFFFAOYSA-N [Zn].C(C1=CC=CC=C1)(=N)N Chemical compound [Zn].C(C1=CC=CC=C1)(=N)N DBYBWCHSXOSECO-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000499 gel Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- DGYWXYFLXYIOCP-KBPBESRZSA-N (2s)-n-[2-[[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]-5-oxopyrrolidine-2-carboxamide Chemical compound N([C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 DGYWXYFLXYIOCP-KBPBESRZSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 230000003024 amidolytic effect Effects 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 108010034748 copper-binding protein Proteins 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000022382 heparin binding proteins Human genes 0.000 description 2
- 108091012216 heparin binding proteins Proteins 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- PBFMTASVGJAKBW-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethylperoxy)ethylperoxymethyl]oxirane Chemical compound C(C1CO1)OOCCOOCC1CO1 PBFMTASVGJAKBW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FAAYDFBUMOADEP-UHFFFAOYSA-N 3-(2,5-dioxopyrrol-1-yl)-3-hexanoyl-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1C=CC(=O)N1C1(C(=O)CCCCC)CC(=O)N(O)C1=O FAAYDFBUMOADEP-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- -1 biological molecules Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- GHEHNICLPWTXJC-UHFFFAOYSA-N p-Aminobenzamidine dihydrochloride Chemical compound [Cl-].[Cl-].NC(=[NH2+])C1=CC=C([NH3+])C=C1 GHEHNICLPWTXJC-UHFFFAOYSA-N 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011240 wet gel Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
Definitions
- This invention relates to methods for separating, purifying and/or identifying a compound from a sample, where the compound has an affinity for at least two ligands.
- the method hereinafter referred to as "bi-affinity chromatography", is particularly useful for the separation, identification and purification of species of fibroblast growth factor through use of a heparin-copper bi-affinity chromatography column.
- Affinity chromatography is a well known process which enables the efficient isolation of biological macromolecules or biopolymers by making use of a feature unique to these substances.
- biopolymers such as enzymes and antibodies are capable of recognizing certain chemical structures with a high degree of selectivity and then binding to them.
- the process of affinity chromatography typically involves a selective adsorbent which is placed in contact with a solution containing several kinds of substances including the desired species, the ligate. The ligate is selectively adsorbed to the ligand, which is attached to an insoluble support or matrix. The nonbinding species are removed by washing.. The ligate is then recovered by eluting with a specific desorbing agent.
- FGFs fibroblast growth factor
- bFGF basic fibroblast growth factor
- aFGF acidic fibroblast growth factor
- heparin can act as a copper chelator (Grushka et al. Analvt. Lett. 15, 1277-1288 (1982)) and Stivala et al. Fed. Proc. 36, 83-88, (1977)).
- the method comprises the steps of (a) contacting the sample with a bi-affinity column comprising two ligands for which the compound of interest has affinity, (b) contacting the column with an eluate which elutes compounds which do not bind to at least one of the two ligands, and (c) contacting the column with an eluate which elutes compounds which have affinity for both of the ligands.
- the method of the present invention has been particularly useful in the separation, identification and purification of various forms or species of fibroblast growth factors in a simple, rapid manner based on the interaction of these growth factors with heparin and copper.
- the present invention has also been useful in the separation, purification and identification of species of urokinase.
- the method for separating, identifying and purifying the various forms or species of FGFs comprises contacting a sample containing FGFs with a bi-affinity chromatography column comprising (i) heparin-Sepharose and (ii) a copper-saturated chelating-Sepharose, both commercially available from Pharmacia AB, Uppsala, Sweden.
- the column is thereafter alternately rinsed with (A) an eluate, such as a concentrated salt solution, which will remove compounds which removably bind to heparin, but not to copper; and (B) an eluate which will remove compounds which removably bind to copper, but not to heparin, e.g.
- the FGF proteins which have affinity to both heparin and copper, are removed from the column by elution with an eluant which will remove such proteins from both the heparin and copper binding sites.
- the eluate contains a combination of materials, which serve to remove the proteins from both the heparin and the copper, depending on the concentration of the materials in the eluate.
- the eluate used to remove the FGF's from the column is a linear NaCl/imidazole gradient. Fractions eluted from the column are collected, analyzed and characterized as to their molecular weight, acidic or basic nature and other properties of ref .
- FGFs may have separate binding sites for copper and for heparin.
- a sample containing FGFs is contacted with a bi-affinity column containing both heparin and copper on the chromatography media
- treatment of the column singly with an eluate which would remove the FGF's from a chromatographic media containing heparin, or with an eluate which would remove the FGF's from a chromatographic media containing copper, leaves FGF's on the bi-affinity heparin/copper media.
- the right eluate is applied, e.g. an increasing concentration gradient of both NaCl and imidazole, not only are FGF's removed from the column, but they are clearly separated in accordance with type (aFGF, bFGF) and size.
- the present invention permits resolution of the various multiple forms of FGFs, based upon bi-affinity chromatography.
- Figure 1 is a schematic illustration of a heparin/copper bi-affinity chromatography column useful in the separation, purification and identification of fibroblast growth factors.
- FIG. 2 illustrates application of heparin/copper bi-affinity chromatography to a sample isolated from bovine hypothalmi.
- Fig. 2A shows the presence and activity of various species of FGFs collected in fractions 6 - 20.
- the inset to Fig. 2A is a depiction of a silver stained gel showing the protein profile prior to heparin/copper bi-affinity chromatography.
- Fig. 2B is depiction of the silver stained fractions collected in Fig. 2A, which samples were previously subjected to SDS gel electrophoresis.
- Fig. 2C and 2D are Western blots of the fractions probed with antibodies raised against basic FGF and acidic FGF respectivel .
- Figure 3 shows the presence and activity of various species of urokinase obtained by application of a benzamidine/zinc bi-affinity chromatography column to a sample isolated from human urine.
- Figure 4 shows two distict peaks obtained by HPLC gel filtration of benzamidine/zinc purified pro-urokinase.
- Figure 5 shows the results of SDS gel electrophoresis of pro-urokinase (Pro-UK) , high molecular weight urokinase (H-UK) and low molecular weight urokinase (L-UK) .
- the method comprises contacting a sample containing the compound of interest with a bi-affinity column comprising two ligands to which the compound releasably binds.
- the column is then contacted with a first eluate which elutes those compounds which releasably bind to one of the two ligands.
- the column is thereafter contacted with a second eluate which elutes compounds which releasably bind to the other ligand.
- this process is continued in an alternating fashion for a sufficient number of times until the undesirable components of the sample have been removed.
- the compound of interest is then recovered by contacting the column with an eluate which elutes compounds which releasably bind to both ligands.
- TPA tissue plasminogen activator
- such compounds can be separated, purified and/or identified by (i) contacting a sample containing the compound of interest with a bi-affinity column comprising both ligands to which the compound has an affinity, (ii) alternately contacting the column with eluates which elute compounds which bind to one ligand but not the other, and (iii) contacting the column with an eluate which elutes compounds which have an affinity for both ligands.
- the eluates which may be used in practicing the present invention will vary depending on the compound of interest, and more particularly on the ligands used to construct the bi-affinity column.
- the eluate used should be one which releases the compound of interest from the metal without breaking the bond between the metal and the matrix used to support the metal.
- Weak chelating agents such as imidazole may be used where the matrix is a metal saturated chelating resin such as Pharmacia's chelating-sepharose.
- the alternate eluate used will be a strong ionic solution such as NaCl.
- the eluates chosen will depend on the ligands used to construct the bi-affinity column as well as the relative affinity of those ligands for the compound of interest. Recovery of the compound from the column may be achieved with a gradient of the eluates used in the alternate eluting steps. Fractions are then collected and analysed for the compound of interest.
- the method of the present invention has been particularly useful in the separation, identification and purification of FGFs.
- the method preferabl comprises the steps of: (i) contacting a sample containing FGFs with a bi-affinity column comprising heparin and copper on a suitable support; and (ii) eluting the species of FGFs with a suitable eluate such as an increasing concentration gradient of materials which are effective to remove the FGF's from the heparin and the copper.
- a suitable eluate such as an increasing concentration gradient of materials which are effective to remove the FGF's from the heparin and the copper.
- the column is rinsed singly with eluates for heparin-binding proteins and for copper-binding proteins prior to the elution of the FGF's themselves.
- the method also involves collecting fractions containing the separated species of FGFs.
- the heparin and copper components of the bi-affinity column are preferably in the form of a mixture or blend of heparin-Sepharose (Pharmacia Fine Chemicals, Sweden) and a copper-saturated chelating-Sepharose (Pharmacia Fine Chemicals, Sweden) , although other suitable heparin-resins such as heparin-agarose (Sigma) and chelating-resins such as iminodiacetic acid-agarose (Sigma) may be used in lieu thereof.
- the chromatographic media is preferably constituted so that the number of available heparin-binding sites is approximately equal to the number of available copper-binding sites.
- the ratio by weight percent of heparin-Sepharose to the copper-saturated chelating-Sepharose is preferably from about 10:1 to about 1:10, and most preferably about 1:1.
- the eluates used in connection with this invention will vary depending on the compound of interest.
- the eluate should not contain materials which react unfavorably with the chromatography medium involved, or with the compounds sought to be recovered.
- such eluates will normally be aqueous solutions containing physiological salt and suitable buffering materials to maintain the pH at around 7.
- the preferred buffering composition is Tris, in a concentration of about 10 mM.
- Preferred eluates for eluting heparin-binding proteins from the column comprise salt solutions, e.g. halides of metals of group 1 or 2 of the periodic table of the elements. NaCl is most preferred, and it can be used in increasing concentration gradients, or in varying concentrations, depending upon the usage and the materials to be eluted.
- Other suitable eluates include sulfates such as (NH 4 ) 2 S0 4 .
- Preferred eluates for eluting copper-binding proteins from the column comprise solutions containing materials, generally organic materials, which have a greater affinity for the metal component in the chromatographic media than the proteins to be eluted so that the materials to be eluted are displaced from their association with the metal without interfering with the bond between the metal and the supporting resin.
- Imidazole is preferred, and can be used in increasing concentration gradients, or in varying concentrations, depending upon the usage and the materials to be eluted.
- the bi-affinity column is pre-equilibrated with an appropriate solution in which the compound of interest is stable, for example for FGF, a 1 to 3M NaCl, 10 mM Tris, pH 7.
- an appropriate solution in which the compound of interest is stable for example for FGF, a 1 to 3M NaCl, 10 mM Tris, pH 7.
- Pre—equilibriation helps to reduce the undesirable sticking of other components of the sample to the ligands used in the bi-affinity column.
- Eluates, reactants and other solutions which come in contact with the compound of interest should also contain suitable buffers and other ingredients in order to avoid undesirable changes in the structure or function of the compound.
- Samples which contain the compound of interest to be separated, identified or purified are preferably partially purified prior to contact with the bi-affinity column of the present invention by, for example, batchwise adsorption to a conventional affinity chromatography column containing a ligand known to bind to that compound. This partial purification helps to prevent overloading of the bi-affinity column with contaminants or other undesirable components of the sample.
- the partially purified sample is applied directly to the pre-equilibrated bi-affinity column.
- the column is thereafter consecutively rinsed with, depending on the size of the column, from about 100 to about 200 ml volumes of one or more eluates to remove materials from the column other than those which bind to both ligands.
- the consecutive rinses comprise alternating rinses in 10 mM Tris, pH 7 of: a 2.0 to 2.5 M NaCl solution and a 10.0 to 20.0 mM solution of imidazole with intervening rinses of a 0.1 to 0.6 M NaCl solution.
- the column is consecutively rinsed with (i) a 2 M NaCl solution, (ii) a 0.6 M NaCl solution, (iii) a 0.6 M NaCl plus a 10 mM imidazole solution, and (iv) a 0.6 M NaCl solution.
- Rinse (i) is to remove those components of the sample which bind to heparin, but not to copper.
- Rinse (ii) is to re-equilibrate the column to allow the protein of interest to bind back to the other ligand, i.e. heparin.
- Rinse (iii) is to remove those components of the sample which bind to copper, but not to heparin.
- Rinse (iv) is to again re-equilibrate the column prior to the ultimate elution of the protein of interest.
- all of rinses (i) through (iv) would tend to remove materials or contaminants which were not bound to heparin, copper or some other component of the chromatography media.
- the FGFs are eluted with an appropriate eluting gradient such as an NaCl/imidazole gradient.
- the NaCl/imidazole gradient preferably comprises a 0 to 0.6 M NaCl without imidazole to a 2 to 3 M NaCl plus a 10 to 20 mM imidazole at a pH of about 7.
- the volume of the gradient depends on the size of the column employed.
- the NaCl/imidazole gradient comprises about 100 ml of 0.6 M NaCl without imidazole to about 100 ml of 2 M NaCl plus 10 mM imidizole at a pH of about 7.
- imidazole is increasing in concentration from 0 to 10 mM
- NaCl is increasing in concentration from 0.6 to 2 M.
- this gradient can be optimized by changing the imidazole and NaCl concentrations to improve separation of the various species of FGF present in the particular sample.
- the flow rate of the eluents will vary depending on a number of factors, including the size of the column. In general, for a 1 cm x 9 cm column containing 7.0 ml of the heparin and copper components, the flow rate is between about 10 ml/hr and about 40 l/hr, preferably between about 15 ml/hr and 30 ml/hr, and most preferably about 20 ml/hr.
- the volume of fractions collected from the column will also vary depending on a number of factors including the resolving power of the column. That is, the greater the resolving power, the greater the fraction that can be collected. In general, for the above described column, the volume of fractions collected is between about 2 and 10 ml, preferably between about 3 and 7 ml, and most preferably about 5 ml.
- fractions eluted from the bi-affinity column in accordance with the present invention may be analyzed by a number of methods to confirm resolution of the compound of interest from the original sample.
- analytical techniques include analysis of mitogenic activity, e.g. , by measuring uptake of tritiated thymidine by quiescent confluent monolayers of BALB/c mouse 3t3 cells, -as described in Klagsbrun et al., Proc. Natl. Acad. Sci. U.S.A. 82, 805-809 (1985)), the disclosure of which is incorporated herein by reference.
- a crude extract of bovine hypothalmi FGF was prepared as follows: Bovine hypothalami (100 g) obtained from Pel-Freez (Rogers, Arkansas) were homogenized in 300 ml of 0.15 M (NH 4 ) 2 S0 4 at pH 6 and extracted by stirring at 4°C for 2 hours. The crude extract was centrifuged at 15,000 X g for 1 hour and the supernatant solution was loaded directly onto a heparin-Sepharose column (1.5 cm X 12 cm) pre-equilibrated with 0.6 M NaCl in 10 mM Tris, pH 7. The column was rinsed with 300 ml of 0.6 M NaCl in 10 mM Tris, pH 7. A sample of crude extract containing FGFs were substantially eluted with 40 ml of 2 M NaCl in the same buffer.
- bovine fibroblast growth factor activity About 7 x 10 5 units of bovine fibroblast growth factor activity were extracted from bovine hypothalmi. More than 95% of this activity bound to heparin-sepharose in 0.6 M NaCl and could be eluted with 2 M NaCl as described below.
- Copper-saturated chelating-Sepharose component was prepared by adding 100 ml of 2 mg/ml copper (II) chloride to 50 ml of chelating-Sepharose (Pharmacia) , followed by several gentle mixings over a one-hour period and decanting.
- a heparin-copper bi-affinity column was prepared by thoroughly mixing 3.5 ml each of heparin-Sepharose (Pharmacia) and copper-Sephar ⁇ se, and placing the mixture in a 7.0 ml column (1 cm x 9 cm). The mixture was blue in appearance.
- the sample (40 ml) of FGF which was partially purified by batchwise adsorption to heparin-Sepharose as described above, was applied directly to this blue color bi-affinity column which had been pre-equilibrated with 2 M NaCl, 10 mM Tris, pH 7.
- the column was rinsed consecutively with 40 ml each of the following reagents, all in 10 mM Tris, pH 7: (i) 2 M NaCl, (ii) 0_6 M NaCl, (iii) 0.6 M NaCl plus 10 mM imidazole, (iv) 0.6 M NaCl.
- FGFs were eluted at a flow rate of 20 ml/hr with a linear NaCl/imidazole gradient from 100 ml of 0.6 M NaCl without imidazole to 100 ml of 2 M NaCl plus 10 mM imidazole in 10 mM Tris, pH 7. Fractions (10 ml) were collected and assayed for growth factor activity.
- growth factor activity was detected starting at about fraction No. 9, which corresponded to eluate containing about 1.3 M NaCl and 5 mM imidazole. About 30% of the initial growth factor activity was recovered. FGF activity was assessed by measuring the incorporation of [ H]thymidine into the DNA of quiescent, confluent monolayers of BALB/c mouse 3T3 cells in 96-well plates as previously described (Klagsbrun et al. Proc. Natl. Acad. Sci. U.S.A. 82, 805-809 (1985)).
- One unit of activity was defined as the amount of growth factor required to stimulate half-maximal DNA synthesis in 3T3 cells (about 10,000 cells per 0.25 ml of growth medium per well).
- protein concentration was estimated by the method of Lowry et al. (Lowry et al. J. Biol. Chem. 193, 265-275 (1951) ) .
- Rabbits were injected at multiple dorsal intradermal sites with 500 ug each of KLH-peptide conjugate emulsified with complete Freund's adjuvant. Animals were boosted regularly at 3-6 weeks intervals with 200 ug of KLH peptide conjugated emulsified in incomplete Fruend's adjuvant. The titer of the antisera after the second booster injection was about 1:15,000 to 1:50,000 as determined in an ELISA using unconjugated peptide as the antigen.
- nitrocellulose - sheet was incubated with antiserum against either bFGF or aFGF and visualized by successive incubations with biotinylated goat anti-rabbit IgG, streptavidin-biotinylated peroxidase complex, and enzyme substrate (4-chloro-l-naphthol) until color develops (Nakane et al. J. Histochem. Cvtochem. 16, 557-560 (1968)).
- Fibrinolytic activity was determined on plasminogen containing bovine fibrin plate.
- the amidolytic activity was measured at 37°C in 50 mM Tris-HCl, pH 7.4 containing 0.038 M NaCl, 0.01% Tween 80 and 1 mM Pyroglu-Gly-Arg p-nitroanilide (s-2444).
- the urokiase activity was expressed in international units by comparison of the amidolytic activity with that to of the international reference preparation of urokinase.
- Enzyme-linked immunosorbent assay was performed using rabbit antibodies raised against human H-UK in a usual way. IgG fractions were isolaed by chromatography of protein A-Sepharose.
- benzamidine-zinc bi-affinity purified pro-UK showed two distinct peaks with Mr 94,000 (peak I) and Mr 54,000 (peak II) when analyzed by HPLC gel filtration with a Diol-300 column eluted with 0.1 M phosphate buffer containing 0.1 M Na 2 S0 3 . Samples from both peaks showed amidolytic activity on Pyroglu-Gly-Arg p-nitroanilide (S-2444) after streptokinase activation.
- Pro-UK can be separated into two components; a Mr. 94,000 pro-UK and a Mr 54,000 pro-UK.
- Mr 94,000 pro-UK broke down to two smaller chains with molecular weights of 54,000 and 23,000.
- Mr 54,000 pro-UK remained the same but the Mr 54,000 H-UK coverted to two smaller chains with molecular weights of about 30,000 and 20,000 under this condition.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Methods for separating, identifying and purifying various proteins such as of fibroblast growth factors and plasminogin activators with a novel bi-affinity chromatography technique.
Description
BI-AFFINITY CHROMATOGRAPHY OF COMPOUNDS WHICH HAVE AN AFFINITY FOR TWO OR MORE LIGANDS
BACKGROUND OF THE INVENTION
This invention relates to methods for separating, purifying and/or identifying a compound from a sample, where the compound has an affinity for at least two ligands. The method, hereinafter referred to as "bi-affinity chromatography", is particularly useful for the separation, identification and purification of species of fibroblast growth factor through use of a heparin-copper bi-affinity chromatography column.
Affinity chromatography is a well known process which enables the efficient isolation of biological macromolecules or biopolymers by making use of a feature unique to these substances. For example, biopolymers such as enzymes and antibodies are capable of recognizing certain chemical structures with a high degree of selectivity and then binding to them. The process of affinity chromatography typically involves a selective adsorbent which is placed in contact with a solution containing several kinds of substances including the desired species, the ligate. The ligate is selectively adsorbed to the ligand, which is attached to an insoluble support or matrix. The nonbinding species are removed by washing.. The ligate is then recovered by eluting with a specific desorbing agent.
While affinity chromatography has been widely used in recent years in connection with a number of
biological compounds, it has only recently found use in the study of angiogenic factors. The term "angiogenesis" was coined earlier in this century to describe the formation of new blood vessels in the placenta. Early experiments involving observation of angiogenesis in wound healing and tumor growth led to speculation that tumor growth might be dependent upon capillary growth. Not until the late 60's, early 70's was it demonstrated that tumors induce capillary growth by the release of a diffusible tumor-derived angiogenic factor.
Purification of these factors was hampered, however, by the lack of suitable bioassays as well as inadequate knowledge of the components of the angiogenic process.
Advances in mammalian cell culture technique as well as an appreciation tha •endothelial cell locomotion and proliferation were major components of angiogenesis led to the isolation and purification of angiogenic factors. Among the first such factors (also referred to as endothelial cell growth factors) to be isolated was basic fibroblast growth factor.
A major breakthrough in the purification of such factors came in 1983 as a result of the observation that endothelial cell growth factors had a marked affinity for heparin. Heparin affinity chromatography has been widely used for the purification of endothelial cell growth factors from a variety of tissue sources since first reported by Shing et al., J. Cell Biol. 97, 395a (1983)), Shing et al.. Science 223, 1296-1298 (1984)), the disclosures of which are hereby incorporated by reference herein.
Since the development of heparin-affinity chromatography, it has been found that virtually all
endothelial cell growth factors bind avidly to heparin. Moreover, on the basis of their respective affinities for heparin and isoelectric points, the heparin-binding endothelial cell irtitogens can be subdivided into two classes of fibroblast growth factor (hereinafter "FGFs") which are typified by basic fibroblast growth factor (hereinafter "bFGF") and acidic fibroblast growth factor (hereinafter "aFGF") , (See, for example, Schreiber et al. J. Cell Biol. 101, 1623-1626 (1985)), and Lobb et al. J. Biol. Chem. 261, 1924-1928 (1986)). More recently, the purification and amino acid sequences of bFGF and aFGF have been established (See for example, Esch et al. Proc. Natl. Acad. Sci. U.S.A. 82, 6507-6511 (1985)) and Gimenez-Gallego et al. Science 230, 1385-1388 (1985)), Esch et al. Biochem. Biophys. Res. Comm. 133, 554-562 (1985)), Burgess et al. Proc. Natl. Acad. Sci. U.S.A. 7216-7220 (1986)), Strydom et al. Biochemistry 25, 945-951 (1986)).
Both bFGF and aFGF have been shown to exist in multiple molecular weight forms. (See Ueno et al. Biochem. Biophys. Res. Comm. 138, 580-588 (1986)), Klagsbrun et al. Proc. Natl. Acad. Sci. U.S.A. 84, 1839-1843 (1987)), Gospodarowicz et al. Endocrinology 117, 2383-2391 (1985)), Baird et al. Regulatory Peptides 12, 201-213 (1985)), Gospodarowicz et al. Endocrinology 118, 82-90 (1986)), Thomas et al. Proc. Natl. Acad. Sci. U.S.A. 81, 357-361 (1984)), Burgess et al. Proc Natl. Acad. Sci. U.S.A. 83, 7616-7220 (1986)), Gautschi et al. Eur. J. Biochem. 160, 357-361 (1986)). All forms of FGFs, however, have been found to be heat and acid labile. This precludes the use of reverse-phase HPLC for their isolation in their native form (Gospodarowicz et al. Mol. Cell. Endocrinol. 46,
187-204 (1986)). Fibroblast growth factors which have a. broad spectrum of target cells in culture have been reported to induce vascular growth (angiogenesis) in vivo (Esch et al. Proc. Natl. Acad. Sci. U.S.A. 82, 6507-6511 (1985)), Thomas et al. Proc. Natl. Acad Sci. U.S.A. 82, 6409-6413 (1985)). There has been speculation that the binding of FGFs to heparin might be copper-dependent (Folkman et al.. Science 235, 442-447 (1987) ) . This idea was based on several reports in the literature indicating that copper levels in tissue could somehow modulate the intensity of the neovascular response to a given angiogenic stimulus. Such reports included the observation that (i) copper ions could augment endothelial locomotion in vitro (McAuslin et al. EXP. Cell Res. 130, 147-157 (1980)); (ii) rabbits on a copper deficient diet are unable to mount an angiogenic response to prostaglandin E-^ (Ziche et al. J. Nat. Cane. Inst. 69, 475-482' (1982)); (iii) both ceruloplasmin and heparin become angiogenic when complexed to copper, but not when deprived of copper (Raju et al. Cancer Res. 44, 1579-1584 (1984)); and (iv) heparin can act as a copper chelator (Grushka et al. Analvt. Lett. 15, 1277-1288 (1982)) and Stivala et al. Fed. Proc. 36, 83-88, (1977)).
Despite the apparent importance of FGF, its exact structure has been the subject of some controversy since its identification. Due to the differences in tissue and species sources as well as purification procedures, it has been difficult to make direct comparisons of the various forms of FGFs isolated in separate laboratories. Furthermore, although it has been well established that both basic and acidic FGFs exist in multiple forms, it has been difficult to isolate them in their native forms in a reproducible
manner. To date the physiological significance of these structurally similar FGFs in various tissues is not clear and until the present invention it has been difficult to isolate them in sufficient quantities for further investigation.
SUMMARY
In accordance with the present invention there is provided methods for separating, purifying and identifying compounds which have an affinity for at least two ligands from a sample. In its simplest form, the method comprises the steps of (a) contacting the sample with a bi-affinity column comprising two ligands for which the compound of interest has affinity, (b) contacting the column with an eluate which elutes compounds which do not bind to at least one of the two ligands, and (c) contacting the column with an eluate which elutes compounds which have affinity for both of the ligands.
The method of the present invention has been particularly useful in the separation, identification and purification of various forms or species of fibroblast growth factors in a simple, rapid manner based on the interaction of these growth factors with heparin and copper. The present invention has also been useful in the separation, purification and identification of species of urokinase.
In one preferred embodiment, the method for separating, identifying and purifying the various forms or species of FGFs comprises contacting a sample containing FGFs with a bi-affinity chromatography column comprising (i) heparin-Sepharose and (ii) a copper-saturated chelating-Sepharose, both commercially
available from Pharmacia AB, Uppsala, Sweden. The column is thereafter alternately rinsed with (A) an eluate, such as a concentrated salt solution, which will remove compounds which removably bind to heparin, but not to copper; and (B) an eluate which will remove compounds which removably bind to copper, but not to heparin, e.g. a weak saline (NaCl) solution containing a relatively high concentration of imidazole. This step removes proteins which do not bind to heparin or copper, and also removes proteins which have affinity to heparin, but not to copper, and proteins which have affinity to copper, but not to heparin. Elution with eluate A can follow elution with eluate B, but it is preferred that elution with eluate B follow elution with eluate A.
The FGF proteins, which have affinity to both heparin and copper, are removed from the column by elution with an eluant which will remove such proteins from both the heparin and copper binding sites. Preferably, the eluate contains a combination of materials, which serve to remove the proteins from both the heparin and the copper, depending on the concentration of the materials in the eluate. Most preferably, the eluate used to remove the FGF's from the column is a linear NaCl/imidazole gradient. Fractions eluted from the column are collected, analyzed and characterized as to their molecular weight, acidic or basic nature and other properties of interes .
While not wishing to be bound by theory, separation of the various species of FGFs may be accomplished because FGFs may have separate binding sites for copper and for heparin. At any rate, it has been discovered that, when a sample containing FGFs is contacted with a
bi-affinity column containing both heparin and copper on the chromatography media, treatment of the column singly with an eluate which would remove the FGF's from a chromatographic media containing heparin, or with an eluate which would remove the FGF's from a chromatographic media containing copper, leaves FGF's on the bi-affinity heparin/copper media. Yet when the right eluate is applied, e.g. an increasing concentration gradient of both NaCl and imidazole, not only are FGF's removed from the column, but they are clearly separated in accordance with type (aFGF, bFGF) and size.
By taking advantage of the unique interactions between heparin, copper and FGFs, the present invention permits resolution of the various multiple forms of FGFs, based upon bi-affinity chromatography.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a schematic illustration of a heparin/copper bi-affinity chromatography column useful in the separation, purification and identification of fibroblast growth factors.
Figure 2 illustrates application of heparin/copper bi-affinity chromatography to a sample isolated from bovine hypothalmi. Fig. 2A shows the presence and activity of various species of FGFs collected in fractions 6 - 20. The inset to Fig. 2A is a depiction of a silver stained gel showing the protein profile prior to heparin/copper bi-affinity chromatography. Fig. 2B is depiction of the silver stained fractions collected in Fig. 2A, which samples were previously subjected to SDS gel electrophoresis. Fig. 2C and 2D
are Western blots of the fractions probed with antibodies raised against basic FGF and acidic FGF respectivel .
Figure 3 shows the presence and activity of various species of urokinase obtained by application of a benzamidine/zinc bi-affinity chromatography column to a sample isolated from human urine.
Figure 4 shows two distict peaks obtained by HPLC gel filtration of benzamidine/zinc purified pro-urokinase.
Figure 5 shows the results of SDS gel electrophoresis of pro-urokinase (Pro-UK) , high molecular weight urokinase (H-UK) and low molecular weight urokinase (L-UK) .
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention there is provided a novel method for separating, identifying, and/or purifying a compound from a sample, where the compound releasably binds or otherwise has an affinity for at least two ligands.
In general, the method comprises contacting a sample containing the compound of interest with a bi-affinity column comprising two ligands to which the compound releasably binds. The column is then contacted with a first eluate which elutes those compounds which releasably bind to one of the two ligands. The column is thereafter contacted with a second eluate which elutes compounds which releasably bind to the other ligand. Preferably this process is continued in an alternating fashion for a sufficient
number of times until the undesirable components of the sample have been removed. The compound of interest is then recovered by contacting the column with an eluate which elutes compounds which releasably bind to both ligands.
As will be appreciated by the skilled artisan, there are many compounds, particularly biological molecules, which releasably bind or otherwise have an affinity for two or more ligands. For example, there are a number of biological molecules, such as enzymes, which are known to bind to metals such as iron, zinc, copper and the like. These enzymes also, by definition, interact, typically by binding with its particular enzyme substrate. Tissue plasminogen activator (TPA) is another example of a biological molecule which is known to bind to at least two ligands. TPA has been shown to bind to zinc (Radcliffe et al., Arch. Biochem. Biophys. 189, 185-194 (1978)) as well as to the amino acid lysine (Rijken et al., J. Biol. Che . 256. 7035-7041 (1981)).
In accordance with the present invention, such compounds can be separated, purified and/or identified by (i) contacting a sample containing the compound of interest with a bi-affinity column comprising both ligands to which the compound has an affinity, (ii) alternately contacting the column with eluates which elute compounds which bind to one ligand but not the other, and (iii) contacting the column with an eluate which elutes compounds which have an affinity for both ligands.
The eluates which may be used in practicing the present invention will vary depending on the compound of interest, and more particularly on the ligands used to construct the bi-affinity column. For example,
where one of the ligands is a metal such as copper or zinc, the eluate used should be one which releases the compound of interest from the metal without breaking the bond between the metal and the matrix used to support the metal. Weak chelating agents such as imidazole may be used where the matrix is a metal saturated chelating resin such as Pharmacia's chelating-sepharose. In many instances, the alternate eluate used will be a strong ionic solution such as NaCl. The skilled artisan will appreciate, however, that the eluates chosen will depend on the ligands used to construct the bi-affinity column as well as the relative affinity of those ligands for the compound of interest. Recovery of the compound from the column may be achieved with a gradient of the eluates used in the alternate eluting steps. Fractions are then collected and analysed for the compound of interest.
The method of the present invention has been particularly useful in the separation, identification and purification of FGFs. The method preferabl comprises the steps of: (i) contacting a sample containing FGFs with a bi-affinity column comprising heparin and copper on a suitable support; and (ii) eluting the species of FGFs with a suitable eluate such as an increasing concentration gradient of materials which are effective to remove the FGF's from the heparin and the copper. Preferably the column is rinsed singly with eluates for heparin-binding proteins and for copper-binding proteins prior to the elution of the FGF's themselves. Preferably the method also involves collecting fractions containing the separated species of FGFs.
The heparin and copper components of the bi-affinity column are preferably in the form of a
mixture or blend of heparin-Sepharose (Pharmacia Fine Chemicals, Sweden) and a copper-saturated chelating-Sepharose (Pharmacia Fine Chemicals, Sweden) , although other suitable heparin-resins such as heparin-agarose (Sigma) and chelating-resins such as iminodiacetic acid-agarose (Sigma) may be used in lieu thereof.
The chromatographic media is preferably constituted so that the number of available heparin-binding sites is approximately equal to the number of available copper-binding sites. When heparin-Sepharose and copper-saturated chelating-Sepharose are employed as the heparin and copper components of the bi-affinity column, the ratio by weight percent of heparin-Sepharose to the copper-saturated chelating-Sepharose is preferably from about 10:1 to about 1:10, and most preferably about 1:1.
As noted above, the eluates used in connection with this invention will vary depending on the compound of interest. In general, the eluate should not contain materials which react unfavorably with the chromatography medium involved, or with the compounds sought to be recovered. To that end, such eluates will normally be aqueous solutions containing physiological salt and suitable buffering materials to maintain the pH at around 7. The preferred buffering composition is Tris, in a concentration of about 10 mM.
Preferred eluates for eluting heparin-binding proteins from the column comprise salt solutions, e.g. halides of metals of group 1 or 2 of the periodic table of the elements. NaCl is most preferred, and it can be used in increasing concentration gradients, or in varying concentrations, depending upon the usage and the materials to be eluted. Other suitable eluates
include sulfates such as (NH4)2S04.
Preferred eluates for eluting copper-binding proteins from the column comprise solutions containing materials, generally organic materials, which have a greater affinity for the metal component in the chromatographic media than the proteins to be eluted so that the materials to be eluted are displaced from their association with the metal without interfering with the bond between the metal and the supporting resin. Imidazole is preferred, and can be used in increasing concentration gradients, or in varying concentrations, depending upon the usage and the materials to be eluted.
For most applications, including application of the present invention to FGFs, the bi-affinity column is pre-equilibrated with an appropriate solution in which the compound of interest is stable, for example for FGF, a 1 to 3M NaCl, 10 mM Tris, pH 7. Pre—equilibriation helps to reduce the undesirable sticking of other components of the sample to the ligands used in the bi-affinity column. Eluates, reactants and other solutions which come in contact with the compound of interest should also contain suitable buffers and other ingredients in order to avoid undesirable changes in the structure or function of the compound.
Samples which contain the compound of interest to be separated, identified or purified are preferably partially purified prior to contact with the bi-affinity column of the present invention by, for example, batchwise adsorption to a conventional affinity chromatography column containing a ligand known to bind to that compound. This partial purification helps to prevent overloading of the
bi-affinity column with contaminants or other undesirable components of the sample.
The partially purified sample is applied directly to the pre-equilibrated bi-affinity column. The column is thereafter consecutively rinsed with, depending on the size of the column, from about 100 to about 200 ml volumes of one or more eluates to remove materials from the column other than those which bind to both ligands. When the compound of interest is FGF, the consecutive rinses comprise alternating rinses in 10 mM Tris, pH 7 of: a 2.0 to 2.5 M NaCl solution and a 10.0 to 20.0 mM solution of imidazole with intervening rinses of a 0.1 to 0.6 M NaCl solution. Most preferably, when the compound of interest is FGF the column is consecutively rinsed with (i) a 2 M NaCl solution, (ii) a 0.6 M NaCl solution, (iii) a 0.6 M NaCl plus a 10 mM imidazole solution, and (iv) a 0.6 M NaCl solution. Rinse (i) is to remove those components of the sample which bind to heparin, but not to copper. Rinse (ii) is to re-equilibrate the column to allow the protein of interest to bind back to the other ligand, i.e. heparin. Rinse (iii) is to remove those components of the sample which bind to copper, but not to heparin. Rinse (iv) is to again re-equilibrate the column prior to the ultimate elution of the protein of interest. Of course, all of rinses (i) through (iv) would tend to remove materials or contaminants which were not bound to heparin, copper or some other component of the chromatography media.
After rinsing, the FGFs are eluted with an appropriate eluting gradient such as an NaCl/imidazole gradient. The NaCl/imidazole gradient preferably comprises a 0 to 0.6 M NaCl without imidazole to a 2 to 3 M NaCl plus a 10 to 20 mM imidazole at a pH of about
7. The volume of the gradient depends on the size of the column employed. For example, for a 1 cm x 9 cm bi-affinity column containing about 7 ml of the heparin and copper components, the NaCl/imidazole gradient comprises about 100 ml of 0.6 M NaCl without imidazole to about 100 ml of 2 M NaCl plus 10 mM imidizole at a pH of about 7. This means that imidazole is increasing in concentration from 0 to 10 mM, and that NaCl is increasing in concentration from 0.6 to 2 M. As will be understood by those skilled in the art, depending on the source of the sample (e.g. brain vs. pituitary tissue) , this gradient can be optimized by changing the imidazole and NaCl concentrations to improve separation of the various species of FGF present in the particular sample.
The flow rate of the eluents will vary depending on a number of factors, including the size of the column. In general, for a 1 cm x 9 cm column containing 7.0 ml of the heparin and copper components, the flow rate is between about 10 ml/hr and about 40 l/hr, preferably between about 15 ml/hr and 30 ml/hr, and most preferably about 20 ml/hr.
The volume of fractions collected from the column will also vary depending on a number of factors including the resolving power of the column. That is, the greater the resolving power, the greater the fraction that can be collected. In general, for the above described column, the volume of fractions collected is between about 2 and 10 ml, preferably between about 3 and 7 ml, and most preferably about 5 ml.
As the skilled artisan will appreciate, fractions eluted from the bi-affinity column in accordance with the present invention may be analyzed by a number of
methods to confirm resolution of the compound of interest from the original sample. For FGFs, for example, such analytical techniques include analysis of mitogenic activity, e.g. , by measuring uptake of tritiated thymidine by quiescent confluent monolayers of BALB/c mouse 3t3 cells, -as described in Klagsbrun et al., Proc. Natl. Acad. Sci. U.S.A. 82, 805-809 (1985)), the disclosure of which is incorporated herein by reference. Other techniques may also be used, such as SDS polyacrylamide gel electrophoresis followed by silver staining, electrophoretic immunoblots using site-specific polyclonal antibodies raised against either bFGF or aFGF. Other techniques such as radioimmunoassay may also be used, as will be readily appreciated by those skilled in the art.
The invention will be further illustrated with reference to the following examples which will aid in the understanding of the present invention, but which are not to be construed as a limitation thereof.
EXAMPLE I Heparin-Copper Bi-affinity Chromatography of FGFs
A. Isolation of FGFs from Hypothalamus A crude extract of bovine hypothalmi FGF was prepared as follows: Bovine hypothalami (100 g) obtained from Pel-Freez (Rogers, Arkansas) were homogenized in 300 ml of 0.15 M (NH4)2S04 at pH 6 and extracted by stirring at 4°C for 2 hours. The crude extract was centrifuged at 15,000 X g for 1 hour and the supernatant solution was loaded directly onto a heparin-Sepharose column (1.5 cm X 12 cm) pre-equilibrated with 0.6 M NaCl in 10 mM Tris, pH 7. The column was rinsed with 300 ml of 0.6 M NaCl in 10
mM Tris, pH 7. A sample of crude extract containing FGFs were substantially eluted with 40 ml of 2 M NaCl in the same buffer.
About 7 x 105 units of bovine fibroblast growth factor activity were extracted from bovine hypothalmi. More than 95% of this activity bound to heparin-sepharose in 0.6 M NaCl and could be eluted with 2 M NaCl as described below.
B. Heparin-copper Bi-affinitv Chromatography Copper-saturated chelating-Sepharose component was prepared by adding 100 ml of 2 mg/ml copper (II) chloride to 50 ml of chelating-Sepharose (Pharmacia) , followed by several gentle mixings over a one-hour period and decanting. A heparin-copper bi-affinity column was prepared by thoroughly mixing 3.5 ml each of heparin-Sepharose (Pharmacia) and copper-Sepharσse, and placing the mixture in a 7.0 ml column (1 cm x 9 cm). The mixture was blue in appearance. The sample (40 ml) of FGF, which was partially purified by batchwise adsorption to heparin-Sepharose as described above, was applied directly to this blue color bi-affinity column which had been pre-equilibrated with 2 M NaCl, 10 mM Tris, pH 7. The column was rinsed consecutively with 40 ml each of the following reagents, all in 10 mM Tris, pH 7: (i) 2 M NaCl, (ii) 0_6 M NaCl, (iii) 0.6 M NaCl plus 10 mM imidazole, (iv) 0.6 M NaCl. Finally, FGFs were eluted at a flow rate of 20 ml/hr with a linear NaCl/imidazole gradient from 100 ml of 0.6 M NaCl without imidazole to 100 ml of 2 M NaCl plus 10 mM imidazole in 10 mM Tris, pH 7. Fractions (10 ml) were collected and assayed for growth factor activity.
C. Growth Factor Assay
As can be seen from Fig. 2A, growth factor activity was detected starting at about fraction No. 9, which corresponded to eluate containing about 1.3 M NaCl and 5 mM imidazole. About 30% of the initial growth factor activity was recovered. FGF activity was assessed by measuring the incorporation of [ H]thymidine into the DNA of quiescent, confluent monolayers of BALB/c mouse 3T3 cells in 96-well plates as previously described (Klagsbrun et al. Proc. Natl. Acad. Sci. U.S.A. 82, 805-809 (1985)). One unit of activity was defined as the amount of growth factor required to stimulate half-maximal DNA synthesis in 3T3 cells (about 10,000 cells per 0.25 ml of growth medium per well). For determination of specific activity and amount of recovery, protein concentration was estimated by the method of Lowry et al. (Lowry et al. J. Biol. Chem. 193, 265-275 (1951) ) .
D. SDS Polyacrylamide Gel Electrophoresis
As illustrated in Fig. 2B, analysis of eluates from fraction 9 to fraction 20 by SDS polyacrylamide gel electrophoresis followed by silver staining revealed the existence of multiple protein bands corresponding to the various FGF species present in bovine hypothalmi. The FGF-containing samples were analyzed by electrophoresis on 15% polyacrylamide gels as described by Laemmli (Laemmli et al. Nature (London) 227, 680-685 (1970)). The polypeptide bands were visualized by a silver stain described by Oakley (Oakley et al. Anal. Biochem. 105, 361-363 (1980)).
E. Preparation of Anti-FGF Polvclonal Antibodies Peptide fragments corresponding to positions 1-12
(Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe) of
basic FGF (Esch et al. Proc. Natl. Acad. Sci. U.S.A. 82, 6507-6511 (1985)) and position 59-90 (Thr-Glu-Thr- Gly-Gln-Phe-Leu-Ala-Met-Asp-Thr-Asp-Gly-Leu-Leu-Tyr-Gly- Ser-Gln-Thr-Pro-Asn-Glu-Glu-Cys-Leu-Phe-Leu-Glu-Arg-Leu- Glu) of acidic FGF (Gimenez-Gallego et al. Science 230, 1385-1388 (1985)) were synthesized by solid phase methods using an automated Applied Biosystems 430 A peptide synthesizer (See Merrifield et al. J. Am. Chem. Soc. 85, 2149-2154 (1963)), Sakakibara et al. Chemistry and Biochemistry of Amino Acids. Peptides and Proteins. 1:51-85 (Weinstein, B., ed. Marcel Dekker, New York 1971)) . The synthetic peptide fragments were conjugated to keyhole limpet hemocyanin (KLH) using maleimidohexanoyl-N-hydroxy-succinimide ester as a cross-linking agent (Ishikawa et al. Immunoassav 4, 209-327, (1983)). Rabbits were injected at multiple dorsal intradermal sites with 500 ug each of KLH-peptide conjugate emulsified with complete Freund's adjuvant. Animals were boosted regularly at 3-6 weeks intervals with 200 ug of KLH peptide conjugated emulsified in incomplete Fruend's adjuvant. The titer of the antisera after the second booster injection was about 1:15,000 to 1:50,000 as determined in an ELISA using unconjugated peptide as the antigen.
F. Immunoblotting .Western blot)
As illustrated in Figs.2C and 2D, further analysis of these protein bands by electrophoretic immunoblot (Western blot) using site-specific polyclonal antibodies raised against either bFGF (Figure 2C) , or aFGF (Figure 2D) demonstrated that it was possible to resolve from hypothalamus at least two bFGF species with Mr values of 19,000 and 18,000 and three aFGF species with Mr values of 18,000, 16,400 and 15,600.
Proteins were separated by electrophoresis on SDS 15%-polyaσrylamide gels and transferred electrophoretically to a nitrocellulose sheet as previously described (Towbin et al. Proc. Natl. Acad. Sci. U.S.A. 76, 4350-4354 (1979)). The nitrocellulose - sheet was incubated with antiserum against either bFGF or aFGF and visualized by successive incubations with biotinylated goat anti-rabbit IgG, streptavidin-biotinylated peroxidase complex, and enzyme substrate (4-chloro-l-naphthol) until color develops (Nakane et al. J. Histochem. Cvtochem. 16, 557-560 (1968)).
EXAMPLE II
Benzamidine/Zinc Bi-affinity Chromatography of Urokinase
Urokinase is a plasminogen-activating enzyme. Extensive work has been done on its purification from urine. These purification procedures yield two different molecular weight forms of the protease: a high molecular weight form (H-UK, Mr=54,000) consisting of two disulfide bonded chains and a low molecular weight form (L-UK, Mr=33,000) consisting of a single chain. Recently, a single-chain inactive form of urokinase, pro-urokinase (Pro-UK, Mr=54,000) which can be activated by limited plasmin digestion has been recognized. Due to the similarity in charge and mass it has been difficult to separate these closely related proteins. Separation of these proteins was achieved in accordance with the present invention as described below.
Two methods were used to assay urokinase activity:
1. Fibrinolytic activity was determined on plasminogen containing bovine fibrin plate. The amidolytic activity was measured at 37°C in 50 mM Tris-HCl, pH 7.4 containing 0.038 M NaCl, 0.01% Tween 80 and 1 mM Pyroglu-Gly-Arg p-nitroanilide (s-2444).. The urokiase activity was expressed in international units by comparison of the amidolytic activity with that to of the international reference preparation of urokinase.
2. Enzyme-linked immunosorbent assay (ELISA) was performed using rabbit antibodies raised against human H-UK in a usual way. IgG fractions were isolaed by chromatography of protein A-Sepharose.
A. Isolation of Urokinase from Human Urine
Crude urokinase with a specific activity of about
6,000 IU/mg was obtained in accordance with the following scheme:
Fresh urine
pH 8.5 Supernatant fraction
Celite 545 Adsorption
Crude Urokinase
B. Benzamidine-zinc Bi-affinity Chromatography A benzamidine-zinc bi-affinity column was prepared in accordance with the following scheme:
Sepharose 4B
Activated Sepharose
Aminodiacetic acid
Na2C03, 5°C, 24 hours
Benzamidine-Zinc Sepharose
Crude urokinase sample (9 mg) prepared as described above was loaded on a benzamidine-zinc bi-affinity column (1.3 X 7.5 cm) equilibrated with 0.2 M NaCl, 50 mM Tris, pH 7.4. No urokinase activity was found in the flow through which contained more than 95% of the total protein. Activiites adhered to the column were eluted consecutively by the following 3 linear gradients:
1. Imidazole gradient (from 0 to 10 mM) in 0.2 M
NaCl, 50 mM Tris, pH 7.4.
2. pH gradient, from pH 7.4 to 4.5 (0.1M NaCl,
0.1 M sodium acetate).
3. EDTA gradient (from 0 to 10 mM) in 0.1 M NaCl,
0.1 M Na acetate, pH 4.5.
The results are shown in the figure 3. As shown in figure 3, the three urokinase-related proteins were clearly separated by the benzamidine-zinc bi-affinity column. While pro-urokinase (Pro-UK) was eluted by the imidazole gradient, high molecular weight form urokinase (H-UK) and low molecular weight form urokinase (L-UK) were separated by the EDTA gradient following the pH gradient. The result of purification is summarized in the following table:
Specific Activity Yield Purification U/mg % . fold
Crude UK 6,000 100 1
Pro-UK 58,000 31 9.6
H-UK 110,000 47 18.3
L-UK 129,000 38.4 21
C. Analysis of Pro-UK bv HPLC Gel Filtration
As shown in Figure 4, benzamidine-zinc bi-affinity purified pro-UK showed two distinct peaks with Mr 94,000 (peak I) and Mr 54,000 (peak II) when analyzed by HPLC gel filtration with a Diol-300 column eluted with 0.1 M phosphate buffer containing 0.1 M Na2S03. Samples from both peaks showed amidolytic activity on Pyroglu-Gly-Arg p-nitroanilide (S-2444) after streptokinase activation.
D. Analyses of Pro-UK, H-UK and L-UK by SDS Gel Electrophoresis
Samples of purified urokinase were analyzed by SDS
Λolyacrylamide gel electrophoresis under non-reducing and reducing (with dithiothreitol) conditions. Results are shown in Figure 5 which are two SDS gels which had been stained by coomassie blue. Molecular weight markers were used for both gels were shown in lane 1: phosphorylase b (94,000), bovin 'serum albumin (68,000), ovalbu in (45,000), arbonic anhydrase (30,000), soybean trypsin inhibitor (21,000), and lysozyme (14,300).
These results demonstrated that Pro-UK can be separated into two components; a Mr. 94,000 pro-UK and a Mr 54,000 pro-UK. Under reducing condition, Mr 94,000 pro-UK broke down to two smaller chains with molecular weights of 54,000 and 23,000. On the other hand, the Mr 54,000 pro-UK remained the same but the Mr 54,000 H-UK coverted to two smaller chains with molecular weights of about 30,000 and 20,000 under this condition.
Claims
1. A method for separating a compound from a sample, the compound being one which has affinity for at least two ligands, comprising the steps of:
(a) contacting the sample with a bi-affinity column comprising two ligands for which the compound has affinity;
(b) contacting the column with an eluate which elutes compounds which do not bind to at least one of the two ligands; and
(c) contacting the column with an eluate which elutes compounds which has affinity for both of the ligands.
2. A method for separating a compound from a sample, the compound being one which releasably binds to at least two ligands, comprising the steps of:
(a) contacting the sample with a bi-affinity column comprising two ligands to which the compound releasably binds;
(b) contacting the column with an eluate which elutes compounds which do not bind to at least one of the two ligands; and
(c) contacting the column with an eluate which elutes compounds which releasably bind to both of the ligands.
3. A method for separating a compound from a sample, the compound being one which releasably binds to at least two ligands, comprising the steps of:
(a) contacting the sample with a bi-affinity column comprising two ligands to which the compound releasably binds; (b) contacting the column with an eluate which elutes compounds which releasably bind to one of the two ligands;
(c) contacting the column with an eluate which elutes compounds which releasably bind to the other of the ligands; and
(d) contacting the column with an eluate which elutes compounds which releasably bind to both of the ligands.
4. The method of claim 3, in which one of the ligands in the column is heparin.
5. The method of claim 4, in which one of the ligands in the column is copper.
6. The method of claim 3, 4 or 5, in which the compound is a protein.
7. The method of claim 6, in which the compound is a growth factor.
8. The method of claim 6, in which the compound is a fibroblast growth factor.
9. The method of claim 6, in which the compound is a human fibroblast growth factor.
10. The method of claim 5, wherein step (b) comprises contacting the column with an eluate which elutes compounds which releasably bind to heparin, step (c) comprises contacting the column with an eluate which elutes compounds which releasably bind to copper; and step (d) comprises contacting the column with an eluate which elutes compounds which releasably bind to both heparin and copper.
11. The method of claim 10, wherein the eluate which elutes compounds which releasably bind to heparin comprises a salt solution.
12. The method of claim 10, wherein the eluate which elutes compounds which releasably bind to copper comprises a salt solution.
13. The method of claim 10, wherein the eluate which elutes compounds which releasably bind to both heparin and copper comprises a salt solution containing imidazole.
14. The method of claim 10, wherein the eluate which elutes compounds which releasably bind to both heparin and copper comprises a salt solution containing imidazole, the amounts of salt and imidazole being linearly increased over time.
15. A method for separating at least one growth factor from a sample, comprising:
(a) contacting the sample with a bi-affinity column comprising heparin and copper;
(b) eluting the fibroblast growth factor with an eluting gradient; and
(c) recovering the fibroblast growth factor.
16. A method for analyzing a sample for at least one fibroblast growth factor, comprising:
(a) contacting the sample with a bi-affinity column comprising heparin and copper; (b) eluting the fibroblast growth factor with an eluting gradient; and
(σ) recovering the fibroblast growth factor.
17. The method of claim 15 or 16, further comprising the steps of:
(i) contacting the column with an eluate which elutes compounds which releasably bind to heparin; and
(ii) contacting the column with an eluate which elutes compounds which releasably bind to copper;
wherein steps (i) and (ii) are conducted before eluting the fibroblast growth factor.
18. The method of claim 17, wherein the growth factor is eluted by contacting the column with an eluate which elutes compounds which releasably bind to both heparin and copper.
19. The method of claim 15 or 16, wherein the heparin and copper components comprise a mixture of heparin-Sepharose and copper-saturated chelating-Sepharose.
20. The method of claim 19, wherein the eluate which elutes compounds which releasably bind to heparin comprises sodium chloride.
21. The method of claim 19, wherein the eluate which elutes compounds which releasably bind to copper comprises imidazole.
22. The method of claim 18, wherein the eluate which elutes compounds which releasably bind to heparin and to copper comprises an eluate having a NaCl/ imidazole concentration gradient.
23. The method of claim 19, wherein the ratio by weight percent of heparin-Sepharose to copper-saturated chelating-Sepharose is from about 1:10 to about 10:1.
24. The method of claim 19, wherein the ratio by weight percent of heparin-Sepharose to copper-saturated chelating-Sepharose is about 1:1.
25. The method of claim 19, wherein the eluate which elutes compounds which releasably bind to heparin comprises from about 100 to 200 ml of a 2 to 3 M NaCl.
26. The method of claim 19, wherein the eluate which elutes compounds which releasably bind to copper comprises from about 100 to 200 ml of 2 to 3 M of NaCl and 10 to 20 mM of imidazole.
27. The method of claim 22, wherein the
NaCl/imidazole gradient comprises from about 100 to 200 ml of a 0.1 to 0.6 M NaCl without imidazole to about 100 to 200 ml of a 2 to 3 M NaCl plus a 10 to 20 mM imidazole at a pH of about 7.
28. The method of claim 27, wherein the
NaCl/imidazole gradient comprises from about 0.6 M to about 2 M NaCl, and from about 0 mM to about 10 mM imidazole.
29. The method of claim 17, wherein the column is contacted with consecutive rinses of: (i) a 2 M NaCl solution; (ii) a 0.6 M NaCl solution; (iii) a 0.6 M NaCl plus a 10 mM imidazole solution; and a (iv) a 0.6 M NaCl solution.
30. A composition of matter comprising a physiologically acceptable chromatography media comprising heparin and copper.
31. The method of claim 3, in which one of the ligands in the column is benzamadine.
32. The method of claim 4, in which one of the ligands in the column is zinc.
33. The method of claim 6, in which the compound is a plasminogen activator.
34. The method of claim 6, in which the compound is urokinase.
35. The method of claim 6, in which the compound is human urokinase.
36. The method of claim 5, wherein step (b) comprises contacting the column with an eluate which elutes compounds which releasably bind to benzamidine, step (c) comprises contacting the column with an eluate which elutes compounds which releasably bind to zinc; and step (d) comprises contacting the column with an eluate which elutes compounds which releasably bind to both benzamidine and zinc.
37. A method for separating at least one urokinase from a sample comprising:
(a) contacting the sample with a bi-affinity column comprising benzamidine and zinc;
(b) eluting the urokinase with an eluting gradient; and
(c) recovering the urokinase.
38. A method for analyzing a sample for at least one urokinase comprising:
(a) contacting the sample with a bi-affinity column comprising benzamidine and zinc;
(b) eluting the urokinase with an eluting gradient; and
(c) recovering the urokinase.
39. A composition of matter comprising a physiologically acceptable chromatography media comprising benzamidine and zinc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1988/000587 WO1989008117A1 (en) | 1988-02-24 | 1988-02-24 | Heparin-copper bi-affinity chromatography of fibroblast growth factors |
USPCT/US88/00587 | 1988-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989008144A1 true WO1989008144A1 (en) | 1989-09-08 |
Family
ID=22208560
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/000587 WO1989008117A1 (en) | 1988-02-24 | 1988-02-24 | Heparin-copper bi-affinity chromatography of fibroblast growth factors |
PCT/US1988/001660 WO1989008144A1 (en) | 1988-02-24 | 1988-05-17 | Bi-affinity chromatography of compounds which have an affinity for two or more ligands |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/000587 WO1989008117A1 (en) | 1988-02-24 | 1988-02-24 | Heparin-copper bi-affinity chromatography of fibroblast growth factors |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO1989008117A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015504A1 (en) * | 1990-04-04 | 1991-10-17 | Sciosnova Inc. | Method to purify basic fibroblast growth factor |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192312A (en) * | 1991-03-05 | 1993-03-09 | Colorado State University Research Foundation | Treated tissue for implantation and methods of treatment and use |
US5331095A (en) * | 1993-04-12 | 1994-07-19 | Scios Nova Inc. | Process for purification of basic fibroblast growth factor |
AU1931495A (en) * | 1994-03-14 | 1995-10-03 | Cryolife, Inc. | Treated tissue for implantation and preparation methods |
-
1988
- 1988-02-24 WO PCT/US1988/000587 patent/WO1989008117A1/en unknown
- 1988-05-17 WO PCT/US1988/001660 patent/WO1989008144A1/en unknown
Non-Patent Citations (6)
Title |
---|
BIOCHEM. BIOPHYS. RES. COMMUN., Vol. 142, No. 2, issued January 1987, (New York, New York, USA), A. BAIRD et al., "Fibroblast Growth Factors are Present in the Extracellular Matrix Produced by Endothelial Cells In Vitro: Implications for a Role of Heparinase-like Enzymes in the Neovascular Response", pages 428-435. * |
BIOCHEM. BIOPHYS. RES. COMMUN., Vol. 146, No. 2, issued July 1987, (New York, New York), M. IWANE et al, "Expression of cDNA Encoding Human Basic Fibroblast Growth Factor in E. Coli", pages 470-477. * |
BIOCHEM. BIOPHYS. RES. COMMUN., Vol. 703, No 1, issued January 1982, (New York, New York, USA), K. BYKOWSKA et al., "Characterization of a Plasminogen Activator Secreted by Cultured Bovine Aortic Endothelial Cells", pages 113-115. * |
BIOCHEMISTRY, Vol. 25, No. 21, issued October 1986, (Washington, D.C.), J.M. ROWE et al., "Purification and Characterization of a Human Pituitary Growth Factor", pages 6441-6425. * |
J. BIOL. CHEM., Vol. 261, No. 3, issued January 1986, (Waghington, D.C. USA), D.C. STUMP et al., "Urokinase-Related Proteins in Human Urine, Isolation and Characterization of Single-Chain Urokinase (Pro-Urokinase) and Urokinase-Inhibitor Complex", pages 1267-1273. * |
J. BIOL. CHEM., Vol. 262, No. 24, issued August 1987, (Washington, D.C. USA), D. GHEYSEN et al., "Characterization of a Recombinant Fusion Protein of the Finger Domain of Tissue-type Plasminogen Activator with a Truncated Single Chain Urokinase-type Plasminogen Activator", pages 11779-11784. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015504A1 (en) * | 1990-04-04 | 1991-10-17 | Sciosnova Inc. | Method to purify basic fibroblast growth factor |
US5136025A (en) * | 1990-04-04 | 1992-08-04 | California Biotechnology Inc. | Method to purify basic fibroblast growth factor |
Also Published As
Publication number | Publication date |
---|---|
WO1989008117A1 (en) | 1989-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Müllertz et al. | The primary inhibitor of plasmin in human plasma | |
Chaga | Twenty-five years of immobilized metal ion affinity chromatography: past, present and future | |
Wiman | Primary structure of the B‐chain of human plasmin | |
Shapiro et al. | Isolation of angiogenin from normal human plasma | |
Rittenhouse et al. | Peptide mapping by polyacrylamide gel electrophoresis after cleavage at aspartyl-prolyl peptide bonds in sodium dodecyl sulfate-containing buffers | |
Shing | Heparin-copper biaffinity chromatography of fibroblast growth factors. | |
US6670455B1 (en) | Process for the preparation in pure form of the protease activating blood clotting VII, its proenzyme or a mixture of both proteins by means of affinity chromatography | |
Huhtala et al. | Biologically active domain in somatomedin-binding protein | |
Baglia et al. | Localization of the high molecular weight kininogen binding site in the heavy chain of human factor XI to amino acids phenylalanine 56 through serine 86. | |
US6677440B1 (en) | Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography | |
Ohlsson et al. | Granulocyte collagenase, elastase and plasma protease inhibitors in purulent sputum | |
WO1989008144A1 (en) | Bi-affinity chromatography of compounds which have an affinity for two or more ligands | |
JPH0676438B2 (en) | Protein isolated from blood, method for producing the protein, and pharmaceutical composition containing the protein | |
JPH1075778A (en) | Peptide bonding with prothrombin and thrombin | |
Fornsted | Affinity chromatographic studies on antigen-antibody dissociation | |
Dempfle et al. | Purification of human plasma fibrinogen by chromatography on protamine-agarose | |
Habal et al. | Kininogens of human plasma | |
Eurell et al. | Purification of swine haptoglobin by affinity chromatography. | |
JPH03233356A (en) | Bi-affinity chromatography of compound having affinity to two or more of legand | |
US6222011B1 (en) | Antigenic peptides | |
Eckersall et al. | Multiple forms of bovine pepsinogen: isolation and identification in serum from calves with ostertagiasis | |
Chawla et al. | Cancer‐Related urinary proteinase inhibitor, EDC1: A new method for its isolation and evidence for multiple forms | |
Högenauer et al. | Isolation and characterization of blood clotting factors VII and X | |
CA2157177A1 (en) | Method and kit for isolation and purification of enzyme-antibody conjugates | |
Moffett | Purification of multiple forms of plasma angiotensinogen: molecular weight and charge heterogeneity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |